Promis Neurosciences could score with out-licensing deals, says Mackie Research
In an update to clients on Wednesday, Mackie Research analyst André Uddin gives a review of Promis Neurosciences’ (Promis Neurosciences Stock Quote, Chart TSX:PMN) discovery and pre-clinical-stage drug candidates and contends that a number of pharma companies are currently interested in out-licensing deals with PMN.
Promis is a pre-clinical-stage neurodegenerative disease biotech company whose lead drug candidate is PMN310, a potentially best-in-class Alzheimer’s drug.
Leaving aside PMN310 in his report, Uddin points to four groups of potential candidates: (1) PMN’s several anti-SOD1 mAb candidates currently in pre-clinical studies; (2) PMN’s TDP43 program which is currently in the lead candidate selection stage; (3) PMN’s the α- synuclein project, for which the company is currently in the lead candidate selection stage; and (4) the tau protein, for which PMN has identified several areas to target.
Uddin says that a monetization opportunity awaits for Promis.
“We expect PMN to out-license these targets/candidates. Very significant licensing deals have been forged by big pharma for the drug targets PMN is focused on. We expect a licensing deal to be forged in Q2 or Q3 2019 – multiple players are currently at the table – to be conservative, we are not assuming any transaction in our model at this time,” says Uddin on Wednesday.
The analyst is maintaining his “Speculative Buy” rating for PMN with a price target of $0.50, representing a projected 12-month return of 56 per cent at the time of publication.
______________________________________________________ An Engine for MedTech Innovation
This article is brought to you by Relay Medical Corp. (CSE:RELA)
Relay Medical is an integrated incubator/accelerator platform, developing a portfolio of medical technologies for pre-commercial exits in the Healthtech marketplace. Click on the logo for more info on this up-and-coming company…
At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.
Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]